Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998076 | 0.83 | MAPK1 (0.41) | MAPK1CNR2P2RX7ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL3069466 | 0.81 | MAPK1 (0.40) | MAPK1CNR2P2RX7LMNAKMT2A | |
| SCHEMBL6110896 | 0.78 | IDE (0.41) | MAPK1CNR2MAPTP2RX7ALDH1A1 | |
| SCHEMBL12764087 | 0.77 | CYP1A2 (0.48) | CNR2MAPTTRPV1GRM2ALDH1A1 | |
| SCHEMBL4406803 | 0.76 | MAPT (0.44) | CNR2MAPTTRPV1GRM2ALDH1A1 | |
| SCHEMBL4408040 | 0.76 | MAPT (0.44) | CNR2MAPTTRPV1GRM2ALDH1A1 | |
| SCHEMBL4405543 | 0.76 | CNR2 (0.41) | CNR2MAPTTRPV1GRM2ALDH1A1 | |
| SCHEMBL4544043 | 0.76 | CNR2 (0.41) | MAPK1CNR2MAPTTRPV1GRM2 | |
| SCHEMBL11767534 | 0.76 | CNR2 (0.41) | CNR2MAPTTRPV1GRM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9661482 | 0.74 | CNR2 (0.41) | CNR2MAPTTRPV1GRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102639-A1 | N-ARYLPYRAZOLE NOD2 AGONISTS AS PROMOTERS OF IMMUNE CHECKPOINT INHIBITOR THERAPY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116066722-A | Integrated modular system for transfer, storage and delivery of Liquefied Natural Gas (LNG) | 伽利略技术公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-3988834-A1 | INTEGRATED MODULAR SYSTEM FOR TRANSFER, STORAGE, AND DELIVERY OF LIQUEFIED NATURAL GAS (LNG) | Galileo Technologies Corporation (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220113086-A1 | INTEGRATED MODULAR SYSTEM FOR TRANSFER, STORAGE, AND DELIVERY OF LIQUEFIED NATURAL GAS (LNG) | COMUSA, INCORPORATED | 2022-04-14 | — | — | US | disclosed |
| US-20210284640-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3760202-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MOLECULAR PROBES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | LIFE TECHNOLOGIES CORP (US) | 2016-05-19 | — | — | US | disclosed |
| US-8318450-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2012-11-27 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20120040380-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | Life Technologies Corporation (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046685-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | MAPK1 2854/4885CNR2 3701/4885MAPT 2935/4885 |
| US-20210284640-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | MAPK1 3032/4885CNR2 3333/4885MAPT 3003/4885 |
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | MAPK1 4586/4885CNR2 4823/4885MAPT 2586/4885 |
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | MAPK1 4586/4885CNR2 4823/4885MAPT 2586/4885 |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | MAPK1 2883/4885CNR2 3688/4885MAPT 2998/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | MAPK1 4047/4885CNR2 106/4885MAPT 2367/4885 |
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | MAPK1 2305/4885CNR2 4167/4885MAPT 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.